Lunaphore launches the 2023 SPYRE™ Immuno-Oncology Grant Program, open to all discovery and translational labs in the field of Immuno-Oncology (IO)

LAUSANNE, Switzerland – March 30, 2022 – 4:00 pm (CET) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the 2023 SPYRE™ Immuno-Oncology Grant Program.  It is a unique opportunity for laboratories looking to adopt spatial biology technology to submit a research project application using a spatial hyperplex IO panel. The Program will award a sample testing project on the COMET™ platform, using any desired SPYRE™ Antibody Panel to two winners. The Grant application is open to all discovery and translational labs located in Europe or North America performing IO research and working with human FFPE samples.

The four SPYRE™ Antibody Panel kits, which include the Immuno-Oncology, Immune, TIL, and T cell Core Panels, lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The panels developed with these kits can be expanded with additional antibodies from Lunaphore’s recommended list, containing more than 70 markers and over 300 protocols, as well as with any additional off-the-shelf, non-conjugated primary antibodies from the researcher’s own library to build custom panels with full flexibility to match their specific research needs.

The new SPYRE™ Antibody Panel kits were designed to support researchers in biomarker identification and validation, allowing scientists to kick-start assay development and enable users with verified biomarkers on COMET™. Lunaphore’s aim with the Grant Program is to further lower the barriers to adopting spatial technology in support of the company’s mission of making spatial biology mainstream.

The winners of the Program will be selected based on the project’s scientific impact and the technology fit of its use case with hyperplex spatial analysis on protein targets with SPYRE™. On top of sample testing, winners will also benefit from different prizes, including future discounts and access to protocols and training.

The submission period will be open from March 30 to May 11, 2023, with the winner announcements taking place on May 25, 2023.

To learn more about the SPYRE™ Immuno-Oncology Grant Program and submit your project for consideration, please visit Lunaphore’s website.

To learn more about Lunaphore, please visit: lunaphore.com/

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

About COMET™

COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/

About SPYRE™ Antibody Panel kits

The four SPYRE™ Antibody Panel kits – Immuno-Oncology, Immune, TIL, and T cell Core Panel – lay the foundation of Lunaphore’s primary antibody offering and establish the basis for the immuno-oncology reagent portfolio. The assays developed with these kits can be modified or expanded with additional off-the-shelf antibodies from the customer’s own library to build custom panels for specific research needs without complexity. The primary antibody offering also includes Panel Builder, an online application providing exclusive access to a library of more than 70 successfully tested off-the-shelf markers and over 300 protocols. It provides an intuitive and convenient way to combine antibodies with SPYRE™ Antibody Panels to create panel protocols in silico, allowing ready-to-use COMET™ hyperplex protocols to be automatically generated in a few clicks. Orders of SPYRE™ Antibody Panel kits can be placed and will be available for shipment by the summer. To learn more about SPYRE™ Antibody Panels, please visit: https://lunaphore.com/spyre-antibody-panels/

For further information contact:

Irene Tamayo

Lunaphore Corporate Communications

Email: [email protected]